market folly

Dmitry Balyasny's hedge fund firm Balyasny Asset Management has filed two separate 13G's with the SEC.

Discloses New Stake in Green Plains Partners

First, Balyasny now owns 6.29% of Green Plains Partners (GPP) with 1 million shares. 

This is a newly disclosed position as Green Plains Partners shares recently started trading at the end of June.  GPP was spun-off from Green Plains (GPRE).

Balyasny previously owned a stake in parent company GPRE but their Q1 13F filing indicates that they exited that position in Q1.

Per Google Finance, Green Plains Partners "owns, operates, develops and acquires ethanol and fuel storage tanks, terminals, transportation assets and other related assets and businesses. The Company operates through four segments: production of ethanol and distillers grains (ethanol production); corn oil production; grain handling and storage and cattle feedlot operations (agribusiness), and marketing, merchant trading and logistics services for self-produced and third-party ethanol, distillers grains, corn oil and other commodities (marketing and distribution). The Company's parent company is Green Plains Inc. The Company owns and operates approximately 27 ethanol storage tanks. Its ethanol storage assets are engaged in storing and loading the ethanol that its parent produces at its ethanol production plants. It provides terminal services and logistics solutions through its fuel terminal facilities. Its transportation assets include a leased railcar fleet of approximately 2,200 railcars."


Balyasny Adds To ChemoCentryx Stake

Second, Balyasny indicates that they own 5.02% of ChemoCentryx (CCXI) with over 2.19 million shares.

This is an increase from the 1.86 million shares they owned at the end of Q1.  The latest filing was made due to activity on June 24th.

Per Google Finance, ChemoCentryx is "a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. The Company's product portfolio includes CCX140, CCX872, CCX168, Vercirnon (Traficet-EN or CCX282) and CCX507."